Skip to main content
. 2016 Sep 1;16(1):708. doi: 10.1186/s12885-016-2737-8

Fig. 1.

Fig. 1

Study design (UMIN000015519). Patients who meet the inclusion criteria are enrolled and randomized. Patients receive 12 weeks’ neoadjuvant therapy with GnRH agonists or degarelix followed by 48 weeks of follow-up after 125I-TPPB. Arrowheads show the time points for assessments